ArticleNeuropsychopharmacology reports2023

Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.

Takami Ishizuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.